01—Abstract
Summary
Summary of the 8-K filed May 29, 2024. Cited figures are marked; the original filing is the authoritative source.
Centene Corporation (CNC) filed an 8-K on May 29, 2024, to provide updates ahead of their investor meetings and the Bernstein Strategic Decisions Conference.
The company is expected to reaffirm its full-year 2024 guidance for adjusted diluted EPS to be greater than $6.80a and a consolidated health benefits ratio between 87.3% and 87.9%. While reaffirming guidance, Centene highlighted some key intra-quarter insights that warrant investor attention. Specifically, the company noted higher-than-expected claims receipts in April and early May for its Medicaid segment, signaling continued elevated medical costs in this area, although a significant portion of Medicaid rate changes are anticipated between July and October 2024.
Conversely, Centene anticipates strong performance in its Marketplace segment for 2024, including favorable risk adjustment outperformance from 2023. The Medicare segment is performing as expected. Importantly, the company's adjusted diluted EPS guidance now incorporates an estimated $125 millionb provision for premium deficiency reserves related to 2025 Medicare Advantage bids, to be recognized in the fourth quarter of 2024.
02—Key points
Key Highlights
- Reaffirmation of 2024 full-year adjusted diluted EPS guidance of greater than $6.80.
- Reaffirmation of 2024 full-year consolidated health benefits ratio range of 87.3% to 87.9%.
- Higher than expected claims receipts and medical costs observed in the Medicaid segment during April and early May 2024.
- Anticipated strong performance in the Marketplace segment for 2024, including favorable 2023 risk adjustment outperformance.
- Medicare segment is on track with 2024 expectations.
- Inclusion of a projected $125 million premium deficiency reserve for 2025 Medicare Advantage bids within the full-year EPS guidance, impacting Q4 2024.
- Expectation of strong consolidated premium, service revenue, and investment income for Q2 and the remainder of 2024.
03—Questions
Frequently Asked Questions
What is the primary reason for Centene's 8-K filing on May 29, 2024?
The primary reason for the 8-K filing is to provide investors with updated insights ahead of Centene's participation in the Bernstein 40th Annual Strategic Decisions Conference and subsequent investor meetings. The company is using this filing to reaffirm its full-year 2024 financial guidance and offer intra-quarter performance updates.
What are the key risks or concerns highlighted for the Medicaid segment?
The main concern for the Medicaid segment is the observation of higher-than-expected claims receipts and medical costs during April and early May 2024. While Centene anticipates that nearly 50% of its Medicaid rate changes will occur between July 1 and October 1, 2024, the current trend indicates elevated medical expenses in the near term.
How will the projected premium deficiency reserve impact Centene's financial results?
Centene has incorporated a projected premium deficiency reserve of approximately $125 million into its 2024 adjusted diluted EPS guidance. This reserve is related to the company's 2025 Medicare Advantage bids and is expected to impact earnings in the fourth quarter of 2024. This suggests potential headwinds or adjustments needed for future Medicare Advantage offerings.
Despite the Medicaid concerns, what are the positive indicators mentioned by Centene?
Centene highlighted strong expected performance in its Marketplace segment for 2024, including favorable risk adjustment outperformance from 2023. Additionally, the company anticipates strong consolidated premium and service revenue, as well as investment income, for the second quarter and the remainder of 2024. The Medicare segment is also performing in line with expectations.
04—Continue